Get the Latest Investment Ideas Delivered Straight to Your Inbox.

TICKERS: RHT; RQHTF

Technical Analyst Expects Health Technologies Firm to Break Higher
Contributed Opinion

Source:

Technical analyst Clive Maund outlines the reasons this stock might break higher.

Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB), which we bought back into at the start of July, has certainly done well for us, as we can see on its latest six-month chart, and the purpose of this update is to point out that the technical pattern continues to look good at this juncture—and that it appears to be accelerating, driven higher by the parabolic uptrend line shown on our chart.

Here is the chart from the July 1 article showing a fine Hod base…


The target for this advance is the CA$1.00–1.10 area, where it will be arriving in a zone of quite strong resistance that we can clearly see on longer-term charts. Unless it breaks down below the parabola or volume becomes very heavy, we will stay long for that.

Note the particularly fine chain of bull flag/pennant consolidations punctuating this advance, and how they are accompanied by a marked volume dieback, which is a sign that another up-leg is incubating. That appears to be the case with the current pennant. Even if it consolidates here for a little longer, it is reasonable to expect it to break higher again soon.

Reliq Health Technologies website.
Reliq Health Technologies closed at CA$0.50; $0.385 at 9.30 a.m. EDT on 4 October 2019.
Originally posted on CliveMaund.com at 9.40 a.m. EDT on 7 October 2019.

PS: If you see any other charts that look this good, please let me know (before they've gone up).

Clive Maund has been president of www.clivemaund.com, a successful resource sector website, since its inception in 2003. He has 30 years' experience in technical analysis and has worked for banks, commodity brokers and stockbrokers in the City of London. He holds a Diploma in Technical Analysis from the UK Society of Technical Analysts.

[NLINSERT]

Disclosure:
1) Clive Maund: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: None. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: None. My company has a financial relationship with the following companies mentioned in this article: None. CliveMaund.com disclosures below. I determined which companies would be included in this article based on my research and understanding of the sector.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports (including members of their household) own securities of Reliq Health Technologies, a company mentioned in this article.

Charts provided by the author.

CliveMaund.com Disclosure:
The above represents the opinion and analysis of Mr Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. Mr. Maund is an independent analyst who receives no compensation of any kind from any groups, individuals or corporations mentioned in his reports. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.




Want to read more about Life Sciences Tools & Diagnostics and Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe